Stempoint Capital LP Has $7.17 Million Stake in Dianthus Therapeutics, Inc. $DNTH

Stempoint Capital LP lifted its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 7.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 85,502 shares of the company’s stock after purchasing an additional 6,218 shares during the period. Dianthus Therapeutics comprises 1.4% of Stempoint Capital LP’s investment portfolio, making the stock its 27th largest holding. Stempoint Capital LP owned approximately 0.16% of Dianthus Therapeutics worth $7,175,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. PNC Financial Services Group Inc. increased its stake in shares of Dianthus Therapeutics by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after buying an additional 139 shares during the period. First Horizon Corp bought a new stake in Dianthus Therapeutics in the first quarter valued at $32,000. Virtus Investment Advisers LLC raised its position in shares of Dianthus Therapeutics by 7.1% during the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after purchasing an additional 416 shares during the period. Royal Bank of Canada increased its position in shares of Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after acquiring an additional 542 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after purchasing an additional 618 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Price Performance

Shares of DNTH opened at $104.09 on Thursday. Dianthus Therapeutics, Inc. has a 1 year low of $18.08 and a 1 year high of $107.99. The stock has a 50 day simple moving average of $91.76 and a two-hundred day simple moving average of $77.61. The firm has a market cap of $5.69 billion, a P/E ratio of -25.20 and a beta of 1.20.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The company had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. On average, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Analyst Ratings Changes

DNTH has been the subject of several analyst reports. Wedbush increased their target price on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Raymond James Financial restated a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $117.82.

Insider Buying and Selling

In related news, SVP Adam M. Veness sold 30,000 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the sale, the senior vice president directly owned 30,000 shares in the company, valued at $2,424,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Ryan Savitz sold 31,249 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the transaction, the executive vice president directly owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 87,779 shares of company stock valued at $7,985,235 over the last three months. 3.02% of the stock is owned by company insiders.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.